A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
Stopped Due to the reconsideration of KHK4827's business in China, it. was decided to withdraw this clinical trial prior to enrollment of first participant.
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
- DRUG: KHK4827-Active
- DRUG: KHK4827-Placebo
Sponsor
Kyowa Kirin Co., Ltd.
Collaborators